Financials
Financial year 2024
KEPHAS PHARMA from Pont-à-Celles, company number BE0793326574, closed financial year 2024 with a result of € 7,346 after tax. For that financial year KEPHAS PHARMA recorded a gross margin of € 13,925 and equity of € 33,505. Compared with financial year 2023, the result moved from € 23,160 to € 7,346. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2025.
€ 33,505
▲ 28% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7,346
▼ 68% vs 2023
Profit after tax over the fiscal year.
€ 34,188
▲ 62% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 30,505.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 3,898
▼ 31% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 20,174
▲ 35% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|
| Gross margin | € 30,726 | € 13,925 | ▼ 55% |
| Profit after taxes | € 23,160 | € 7,346 | ▼ 68% |
| Equity | € 26,160 | € 33,505 | ▲ 28% |
| Total debts | € 20,630 | € 24,071 | ▲ 17% |
| Cash | € 21,070 | € 34,188 | ▲ 62% |
| Retained profit | € 23,160 | € 30,505 | ▲ 32% |
| Balance sheet total | € 46,790 | € 57,577 | ▲ 23% |
Key figures of KEPHAS PHARMA, fiscal years 2023 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to KEPHAS PHARMA?
What happened at KEPHAS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 7,346 (▼ 68% vs 2023). Source: NBB ↗
- New establishment in Pont-à-Celles. KBO
- Pierre Ayelé Atéba became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 23,160 profit in 2023 to € 7,346 profit in 2024.
Paid € 8,233 in corporate taxes since 2023.
Best year ever: 2023, with € 23,160 profit.
Management
Behind KEPHAS PHARMA is Pierre Ayelé Atéba.
Directors
According to the 2024 annual accounts
Pierre Ayelé Atéba
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Rue du Cheval Blanc(LUT) 55
6238 Pont-à-Celles
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0793.326.574
- VAT number
- BE 0793.326.574
- Registered office
- Rue du Cheval Blanc(LUT) 55, 6238 Pont-à-Celles
- Names & denominations
- KEPHAS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 November 2022
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Overige niet-gespecialiseerde detailhandel
Overige vormen van onderwijs
Detailhandel via postorderbedrijven of via internet